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Abstract—In this paper, we examine a well-established model
for HIV wild-type infection. The algorithm for steepest descent
method for fixed final-time is stated and a modified method
for free final-time is presented. The first type of cost functional
considered, seeks to minimize the total time of therapy. An easy
implementation for this problem suggests that it can be effective
in the early stages of treatment as well as for individual-based
studies, due to the “hit first and hit hard” nature of optimal
control.
An LQR based cost functional is also presented and the solu-
tion is found using steepest descent method. It suggests that the
optimal therapy must remain high until the patient shows signs
of recovery after which, the therapy gradually decreases. This
is in line with the biomedical philosophy. Solution to a modified
problem which includes a weight for total time is approximated
using the modified algorithm. It shows a considerable drop in
the total period. We conclude that, a decreased and optimized
therapy period can help us increase efficiency as well as the
turnover rate for patient care.
I. INTRODUCTION
The World health organization (WHO) classifies human
immunodeficiency virus (HIV) as a pandemic. HIV progresses
into acquired immunodeficiency syndrom (AIDS) which leads
to immune system failure. By 2006, AIDS has claimed over 25
million lives and over 0.6% of the world population is infected
with HIV[1].
HIV is responsible for the selective depletion of CD4+
cells, also known as helper T cells. As they are essential
to immune regulation, such depletion leads to an adverse
effect on the immune system functioning [2]. Even though
HIV is rarely fatal by itself, it increases vulnerability towards
infections and malignancies [3]. There is no known cure for
HIV/AIDS as the available drug regimens fail to eliminate HIV
strains in overall population [4]. The antiretroviral treatments
available are mostly administered in “drug-cocktail” form,
also known as highly active antiretroviral therapy (HAART).
Even though HAART has been highly effective in treating
HIV/AIDS, it leads to numerous side-effects from hepatitis,
liver failure, cardiovascular malfunction, pancreas damage to
nausea, diarrhea and depression [3]. In most patients, the ther-
apy is long-term and therefore, the search for optimal therapy
stems from the notion of maintaining a balance between the
disease and drug side-effects to minimize patient suffering.
Several models have been proposed for different types of
HIV therapies. Many of these models study the host-pathogen
reaction for the virus strain HIV-1 through medical studies or
numerical simulations [3]. McLean and Nowak [5] address
the appearance of AZT-resistant strains and its effects on
treatment. Agur [6] and Agur and Cojucaru [7] examine the
effects of chemotherapy on uninfected cells. Much of the
research is also dedicated to acquired infections in an HIV
patient [3]. Compartment infections are studied and modeled
in [8] and [9]. Microphage infections are addressed in [10],
whereas, transient viremia is discussed in [11].
In this paper, we discuss the wild-type infection model
given in [3]. This model is a combination of several of the
previous models, including, [12], [13], and [2]. This model
encapsulates four different therapies : protease inhibitors, HIV
fusion inhibitors, T cell enhancer and HIV reverse transcrip-
tase inhibitor. In this paper, we study the treatment with
protease inhibitors.
II. HIV MODEL FOR WILD-TYPE INFECTION
This paper uses the model given by Stengel [3] for wild-type
infectious HIV. The model is given by four coupled-ODEs and
their elements are the HIV particles (x1), uninfected Th cells
(x2), proviral Th cells (x3) and productively infected Th cells
(x4) (all in per mm3). The different therapies are protease
inhibitors (u1), HIV fusion inhibitors (u2), T cell enhancer
(u3) and HIV reverse transcriptase inhibitor (u4). The model
is given by the following ODEs,
x˙1 = −a1x1 − a2x1x2(1− u2) + a3a4x4(1− u1)
x˙2 =
a5
1 + x1
− a2x1x2(1 − u2)(1 − u4)− a6x2
+a7
(
1−
x2 + x3 + x4
a8
)
x2(1 + u3)
x˙3 = a2x1x2(1 − u2)(1 − u4)− a9x3 − a6x3
x˙4 = a9x3 − a4x4 (1)
The virus particles (x1) have a death rate of a1. x1 infect
the uninfected T cells (x2) at rate a2. This is partially blocked
by HIV fusion inhibitors with efficacy u2. A portion (1-u1)
of the production of x1 from the productively infected cells
(x4) is blocked by the protease inhibitors with efficacy u1.
Birth rate of x2 is proportional to a5 and depends on the
amount of virus present in the system. The conversion of x2
to proviral Th cells (x3) occurs at a rate a2 and is targeted
by HIV reverse transcriptase inhibitor (u4). x2 has a natural
death rate of a6 and a proliferation rate of a7. Proliferation is
enhanced by T cell enhancer (u3). Proviral Th cells (x3) are
produced through infection. x3 convert into x4 at a rate a9
and have a death rate of a6. The infected cells (x4) convert
into virus (x1) at rate a4 with the ratio 1:a3, completing the
cycle. The parameter values (from [3] and [12]) are a1 = 2.4,
a2 = 2.4× 10
−5
, a3 = 1200, a4 = 0.24, a5 = 10, a6 = 0.02,
a7 = 0.03, a8 = 1500, a9 = 0.003.
We define the vectors x = [x1 x2 x3 x4]⊤ and u =
[u1 u2 u3 u4]
⊤
, then equation (1) can be written as x˙ =
f(x(t),u(t), t). The initial conditions are given by x(0) = x0.
We assume that, the drug efficacy for drug i, ui varies between
[ui, ui] and as the efficacies are normalized this is a subset
of [0, 1]. In this paper, we discuss the therapy with protease
inhibitors (u1) and take u2 = u3 = u4 = 0.
III. OPTIMAL CONTROL THEORY
A general optimal control problem can be stated as a
combination of a system of ordinary differantial equations
(ODEs), which defines the dynamics of the state variables
and controls along with a cost functional, which is to be
minimized. The problem is defined over a time period [to, tf ],
where tf can be predefined or free. Consider a system given
by x˙ = f(x,u, t), x(0) = x0 and a cost functional given by,
J = K(x(tf ), tf ) +
∫ tf
to
L(x(t),u(t), t)dt.
If the final time is free, another constraint can be put on the
final state of the system : Ψ(x(tf ), tf ) = 0, where Ψ is a
smooth function. Hamiltonian for this system is defined by,
H(x,u, λ, t) = L(x,u, t)+λ(t)f(x,u, t). The necessary con-
ditions for a minimum are achieved by defining the modified
cost functional J˜ using lagrangian multipliers λ(t) and p as,
J˜ = K(x(tf ), tf ) + pΨ(x(tf ), tf ) +∫ tf
to
[
L(x(t),u(t), t) − λ⊤(t)(f(x(t),u(t), t) − x˙)
]
dt.
The cost functional reaches minimum when the variation,
δJ˜ = 0 with respect to all variables, λ, p,x,u and x(tf )
(also, tf , if final-time is free). Using this argument, if x∗(t)
and u∗(t) are the optimal state and control vectors for time
t respectively then we can state the Pontryagin’s necessary
conditions as following,
1) Ψ(x∗(tf ), tf ) = 0 (Final State Constraint)
2) x˙∗ = ∇λH = f(x∗(t),u∗(t), t) (State Equation)
3) λ˙ = −∇x∗H (Costate Equation)
4) ∇u∗H = 0 (Optimal Control)
5) x(to) = x0
λ(tf ) = ∇x(tf )(K + p
⊤Ψ)
H(tf ) = −∇tf (K + p
⊤Ψ) (Boundary Conditions)
As for the sufficient conditions, where one is concerned with
the local minimality, it is given by ∇2u∗H > 0 (Positive
definite). For global minimality, one must consider all possible
controls over time [to, tf ]. A Hamiltonian convex in u can
ensure the global minimality.
If the final time is free, only the first two boundary condi-
tions are valid. Furthermore, if there is no final state constraint,
the second boundary condition becomes, λ(tf ) = ∇x(tf )K.
One of the most widely used cost functional is the Linear-
Quadratic Regulator (LQR) given by,
J =
1
2
x
⊤(tf )Sx(tf )+
∫ tf
to
1
2
[
x
⊤(t)Qx(t) + u⊤(t)Ru(t)
]
dt.
The matrices, S,Q,R are the weights for the final state
configuration, integral value of state and control, respectively.
If the final time is free, one may add a scalar T in the integral
to include the weight for total time.
A. Algorithm for fixed final-time optimal control problems
As it can be seen from the necessary conditions, the
optimal control system comprises a forward state equation
and a backward costate equation. For nonlinear models the
algorithms are essentially iterative. One of the very effective of
these algorithms is the steepest descent method. The solutions
in this paper are approximated using this algorithm [14].
1) Approximation starts with an initial guess u(t) =
u
(0)(t).
2) x(0)(t) is integrated numerically over time [to, tf ] using
control u(0)(t) with x(0) = x0 as the boundary condi-
tion.
3) Similarly, the costate equation λ˙ = −∇
x
(0)H is numer-
ically solved with λ(tf ) = ∇x(tf )K as the boundary
condition.
4) The gradient ∇
u
(0)H is evaluated using numerical tech-
niques and the updated control for the next iteration is
given by,
u
(1)(t) = u(0)(t)− τ(0)∇
u
(0)H.
Similarly, the k+1-th iteration in terms of uk(t) is given
by,
u
(k+1)(t) = u(k)(t)− τ(k)∇
u
(k)H.
5) This iterative procedure is repeated until some con-
vergence criterion such as, ||u(k+1) − u(k)|| < tol or
J (k) − J (k+1) < tol is satisfied.
B. Modified algorithm for free-final time problems
If the final time is free, the algorithm can be modified to
encapsulate it by updating the control as well as the grid
size for numerical integration in every iteration. For a small
variation ∆tf , one can write ∆J = δJδtf ∆tf . For LQR, this
can be written as,
∆J =
[
x⊤(tf )S∇tfx(tf )
]
∆tf +
1
2
[
x
⊤(tf )Qx(tf ) + u
⊤(tf )Ru(tf ) + T
]
∆tf
= x⊤(tf )Sf(x(tf ), u(tf ), tf )∆tf +
1
2
[
x
⊤(tf )Qx(tf ) + u
⊤(tf )Ru(tf ) + T
]
∆tf
(2)
Suppose, one expects to reduce J by 10%, then one can
change tf using the following equation,
∆tf = t
(k+1)
f − t
(k)
f = −
0.1
δJ
δtf
,
where, t(k)f represents the k-th iteration. Note that, if the
number of grid points is n and the grid length at the k-th
iteration is h(k) then t(k)f = (n − 1)h(k). Therefore, at every
iteration the grid length can be updated as,
h(k+1) = h(k) −
τh(k)
(n− 1) δJ
δtf
.
This condition corresponds to the third boundary condition
specified in the last section, i.e., δJ
δtf
= H(tf ) + ∇tfK.
However, this algorithm cannot be effective when the problem
is specified with a final state constraint (Φ).
IV. RESULTS AND DISCUSSIONS
A. Minimum-time problem
In minimum-time problems, the cost functional is defined
as J = tf − to =
∫ tf
to
dt. They are often presented with
an acceptable set Ω of final state variables, i.e., the value of
Φ over this set is zero. The problem specified in the next
paragraph can be solved using the iterative method described
in the last section by continuing the process until the system
either enters the set Ω or leaves it, but as there is no incentive
for the control to be any less than its maximum value, another
way to define these problems is to find the minimum time it
takes for the system to enter set Ω. Using this notion, we can
solve the problem with an error of the order of the grid size
used for numerical integration.
For the system at hand, the set Ω is taken as the values
of virus particles below a certain level, often called the
detection level. We take the detection level to be 0.05 [15].
The minimum-time problem can be stated as : To find an
admissible control u∗1 : [0, tf ] → [u1, u1] and the final time
tf , which for the system x˙ = f(x(t),u(t), t),x(0) = x0
minimizes the cost functional J = tf − to = tf such that
the final virion population is below the detection level. Here,
the boundary conditions are taken as x1(0) = 30.0, x2(0) =
904, x3(0) = 3.4, x4(0) = 0.46 and u1 = 0.9, [16] for
pharmacokinetic models for HIV suggest that the efficacy
decays exponentially and a perfect efficacy throughout the
treatment period is unlikely to be achieved. The solution to
this problem is presented in Figure 1 and Figure 2. The results
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Fig. 1. States for min-time problem
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Fig. 2. Control for min-time problem
suggest that it takes about 19 weeks for the virus to climb
down below the detection level.
This type of method can be used for finding the optimal
therapy for curable or highly manageable infections or for
drugs with minimal side-effects, where a full-blast treatment
is not detrimental, since the main cause of suffering originates
from the time the infection is active in the system. This method
can also be useful in an early detection or treatment for the
disease, as we shall see in the next subsection that the therapy
remains at its highest under these conditions. The maximum
efficacy can be averaged over one period of administering
drugs for a full-blast therapy. The easy implementation of the
aforementioned procedure leaves room for studies based on
individual patient scenarios [17].
B. Fixed final-time problem
In this section, as a prerequisite to the free final-time
problem, we develop a fixed final-time cost functional (after
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Fig. 3. States for fixed final-time problem
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Fig. 4. Control for fixed final-time problem
[3]) which sheds light on some of the key features of the
optimal control. We take x1(0) = 4.9, x2(0) = 904, x3(0) =
0.34, x4(0) = 0.42 and tf = 500 days. The cost functional is
given by,
J =
1
2
x
⊤(tf )Sx(tf )+
∫ tf
to
1
2
[
x
⊤(t)Qx(t) + u⊤(t)Ru(t)
]
dt,
where, S, Q and R are diagonal matrices. We wish to design
a problem that minimized the terminal and integral values of
proviral T cells (x3), productively infected cells (x4) and the
virus (x1) as well as the integral value of the control (u1).
Keeping these goals in mind, we take the weights to be,
S11 = S33 = S44 = 10
3
, Q11 = Q33 = Q44 = 10
3 and
R11 = 0.01 [3]. The solution is approximated by steepest de-
cent method described in the previous section and is presented
in Figure 3 and Figure 4.
The results suggest that the optimal therapy (u∗) stays at
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Fig. 5. States for free final-time problem
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Fig. 6. Control for free final-time problem
its maximum for about 230 days and then gradually declines
over the rest of the period. This is in sync with the bio-
medical philosophy of “hit first and hit hard” [3], i.e., to
treat the disease with high dosage in the early phase of the
treatment and once a physical recovery takes place, gradually
decrease the dosage. The physical recovery is represented by
the uninfected Th cell count, which rises to almost its highest
in the first 230 days [14]. Similarly, the proviral count and the
productively infected T cells have gone down substantially.
Simulations run over a larger or smaller periods along with
varied values of S,Q, and R suggest that the period of high
efficacy does not vary by much as long as the values of
R stay relatively low. This suggests that when treating with
drugs with minimal side effects, the length of this period stays
approximately the same [14].
This kind of studies of optimal therapy are very common
and successful, as they reflect the well-accepted conceptions
of the bio-medical field. They do, however, fail to address
the time window for which the therapy continues. This is not
reflected through the drug side-effects, especially, if they are
considerably high, for the optimal efficacy changes with the
period of treatment. Therefore, it is important to take time into
account when trying to minimize the cost functional.
C. Free final-time problem
In this section, we present the model for a free final-time
LQR. We state the optimal control problem as the following,
To find an optimal control u∗1 : [0, tf ] → [0, 1] which, for
the system x˙ = f(x(t),u(t), t), minimizes the cost functional,
J =
1
2
x
⊤(tf )Sx(tf ) + T tf
+
∫ tf
0
1
2
[
x
⊤(t)Qx(t) + u⊤(t)Ru(t)
]
dt,
where, the weights S, Q and R serve the same purpose as
before and the added term T tf adds a cost for the duration
of therapy. The values used are, S11 = S33 = S44 = 103,
Q11 = Q33 = Q44 = 10
3
, R11 = 0.01 and T = 0.001. The
initial state of the system is taken to be the same as for the
previous problem, i.e., x1(0) = 4.9, x2(0) = 904, x3(0) =
0.34, x4(0) = 0.42.
To solve this problem, the algorithm described in section
2 is implemented. δJ
δtf
is given by equation 2 and the grid
length h is updated after every few iterations. As mentioned
in section 2, this method tries to satisfy one of the boundary
conditions, namely, H(tf )+∇tfK = 0. An implementation in
MatLabTM shows a considerable drop in this value from the
initial state. The results are presented in Figure 5 and Figure
6.
As the results suggest, we notice a substantial drop in the
treatment window from 500 days to about 275 days. However,
the essential features of the therapy described in the last
subsection are retained in Figure 6. The optimal therapy stays
at its highest for the first 120 days and then shows a gradual
decrease. This, as noted before, coincides with the restored
T cell count and the decreased adverse element counts in
the system. As given in the last subsection, this period of
high efficacy varies (from 230 days to 120 days) when treated
over a different time window. The state variables show similar
progression over time under the two optimal therapies. The
method decreases the total period of therapy while keeping
the state variables as intact as possible.
CONCLUSION
In this paper, we consider a well established model for
wild-type HIV infection. A common LQR optimal therapy
is approximated with the steepest descent method. We, also,
present a modified algorithm for approximating the solution
for free final-time problems.
A minimum-time problem is stated and the solution is
approximated with a non-iterative method. We conclude that,
due to the simple implementation and the “hit first and hit
hard” nature of the optimal therapy, this kind of studies can
be very useful in the first phase of therapy and also provide an
advantage for individual-based optimal-therapy considerations.
The second cost functional is an LQR defined over a
fixed time period, which indicates similarities of the optimal
control with biomedical philosophies. The optimal therapy
shows a period of high efficacy in the first phase and a
gradual decrease once there is physical progress in patient. A
modified problem with free final-time is approximated using
the algorithm mentioned earlier. It shows a considerable drop
in the total period. An optimized time window for treatment
can help us treat patients more efficiently. More number of
patients can be treated if the optimal period for therapy is
lower.
The method presented in this paper is quite similar to
methods already in use. The need for optimizing the therapy
period is quite essential as a higher or lower time period
suggests a non-optimal exposure to either the disease or
therapy.
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